CAR-T Cell Therapy in Acute Lymphoblastic Leukemia

Abstract

Acute Lymphoblastic Leukemia (ALL) is a common blood malignancy tumor that originates from the uncontrolled growth of immature lymphocytes. This process destabilizes normal hematopoiesis and gradually deteriorates the health of patients. There are some conventional treatments such as chemotherapy and hematopoietic stem cell transplantation can improve survival for some patients. However, regarding Relapsed or Refractory (R/R) cases, their efficacy remains very limited, which is a significant challenge in clinical practice. To address these challenges, Chimeric Antigen Receptor T-cell (CAR-T) therapy has unveiled an innovative immunotherapeutic therapy. By carrying out genetic engineering on autologous T cells of patients, this strategy allows them to accurately identify and eradicate malignant lymphoblasts. Among these strategies, CD19-directed CAR-T therapy has accomplished notable clinical breakthroughs. Research shows that 70% to 90% of patients suffering from R/R ALL achieve total remission after receiving CAR-T therapy. In most cases, minimal residual disease becomes undetectable within a relatively short period. These findings also reflect this therapy can induce rapid remission and offer patients improved long-term survival outlook. At the same time, research in this field is expanding. But, in relation to safety hurdles including Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), the risk of relapse in certain patients, and the logistical challenges posed by complex manufacturing and high costs. This research explores recent research on CAR-T therapy in ALL, highlighting both its treatment developments and existing limitations. The purpose is to provide a thorough understanding that may advise future clinical practice and translational research.